NasdaqGM:ALTBiotechs
Medicare Obesity Drug Coverage Puts These 3 Biotech Stocks In Focus
The sudden decision for Medicare to temporarily cover obesity drugs like Wegovy and Zepbound has put a spotlight on pharmaceutical companies working in obesity and metabolic disorders. With millions of eligible seniors now facing a defined $50 monthly copay and a clear end date for coverage in 2027, the stakes are high for both investors and patients. This article looks at how that catalyst connects to three stocks exposed to the news, all drawn from a focused screener of larger healthcare...